Understanding Clinical Trials for Peptide Drugs
A guide to how clinical trials work for peptide-based drugs, what Phase I, II, and III trials test, how to find trial data, and what level of evidence is needed before a peptide's effects can be considered established in humans.
A clinical trial is a systematic research study conducted in human participants to evaluate the safety, pharmacokinetics, or efficacy of an intervention. For peptide-based drugs, the path from a promising pre-clinical compound to regulatory approval requires a structured sequence of trial phases, each with distinct objectives and regulatory checkpoints.
Understanding clinical trial phases is essential for anyone evaluating claims about peptide research. The phrase "there is a study showing this peptide works" means something very different depending on whether "the study" is a Phase I safety trial, a Phase III efficacy trial, or an unregistered observational study.
The Pre-Clinical Phase
Before human trials begin, a compound must undergo extensive pre-clinical characterization:
In vitro studies: Receptor binding assays, cell-based activity studies, cytotoxicity screening. These establish the mechanistic basis for human study and identify potential safety signals.
Animal pharmacology: Dose-response studies in rodent and non-rodent models. Establishes pharmacokinetic parameters (absorption, distribution, metabolism, excretion) and provides early efficacy signal.
Animal toxicology: Acute and repeat-dose toxicity studies in at least two species (typically rat and dog or monkey). Required to establish a safety margin and identify target organs for toxicity before human exposure.
IND Application: In the US, a sponsor must file an Investigational New Drug application with the FDA to legally administer an unapproved drug to human subjects. The IND includes pre-clinical data, manufacturing information, and the protocol for the proposed Phase I trial.
Phase I: Safety and Pharmacokinetics
Objective: Establish that the compound can be administered to humans at some dose range without unacceptable toxicity. Characterize human pharmacokinetics.
Population: Typically 20–100 healthy volunteers, unless the compound's toxicity profile makes this inappropriate (some cancer drugs go directly into patients).
Design: Usually open-label (no blinding), dose-escalating (start low, increase in successive cohorts). Includes serial blood sampling for PK analysis.
What it establishes: Maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), half-life, clearance, volume of distribution.
What it does not establish: Whether the drug works. Phase I is purely about safety and PK.
A peptide that has "completed Phase I trials" has only demonstrated that it can be administered to some number of humans without immediate serious adverse events at some dose range. No efficacy has been established.
Phase II: Early Efficacy and Dose Selection
Objective: Obtain preliminary evidence of efficacy in the target patient population. Refine the dose range for Phase III.
Population: 100–500 patients with the target condition.
Design: Usually randomized and controlled, increasingly blinded. May include multiple dose arms.
What it establishes: Whether there is a biological signal suggesting the drug may work in the intended population. Informs the dose(s) to take forward.
What it does not establish: Definitive proof of efficacy. Phase II trials are often underpowered to detect modest effects reliably and may have inadequate follow-up duration.
ConjuChem's CJC-1295 development program and bremelanotide's early HSDD data represent Phase II-level evidence — promising signals that informed Phase III design.
Phase III: Pivotal Efficacy Trials
Objective: Definitively establish whether the drug produces a clinically meaningful improvement vs. placebo or active comparator in a representative population.
Population: 1,000–30,000+ patients (varies enormously by indication and expected effect size).
Design: Randomized, double-blind, placebo-controlled (or active comparator). Pre-registered primary endpoints. Adequate power to detect the expected effect size.
What it establishes: Efficacy in the studied population at the studied dose and duration. Safety in a larger population than Phase I/II.
What approval means: The drug's benefits outweigh its risks for the specified indication in the specified population. Approval is indication-specific and does not generalize to other uses.
The RECONNECT trials (bremelanotide), STEP trials (semaglutide), and SUSTAIN-6 (semaglutide CV outcomes) are examples of Phase III trials that supported regulatory approval.
How to Find Clinical Trial Data
ClinicalTrials.gov: The primary US registry of clinical trials. All trials of FDA-regulated drugs/devices must be registered here after 2017. Search by compound name, NCT number, or indication. For guidance on evaluating the papers you find, see How to Read a Peptide Research Study.
PubMed: Full-text trial publications. Best for finding peer-reviewed Phase II and III reports with full methodology and statistical analysis.
EU Clinical Trials Register: European equivalent of ClinicalTrials.gov.
WHO International Clinical Trials Registry Platform: Aggregates registries from many countries.
Red Flags in Clinical Evidence Claims
When evaluating claims about peptide efficacy, watch for:
- "Studies show" without specifying Phase, population, or sample size
- Citing animal studies as establishing human effects
- Confusing Phase I safety data with efficacy evidence
- Studies from unregistered trials or unregulated research settings
- Single-center trials without independent replication
- Composite endpoints that obscure which component drove results
- Industry-funded trials without independent statistical analysis
The standard for claiming that a peptide "has been shown to" produce a specific clinical effect in humans is a pre-registered Phase III randomized controlled trial with adequate power, appropriate blinding, and peer-reviewed publication. This standard is high. Most research peptides currently used outside of pharmaceutical development have not met it.